Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
- PMID: 19920816
- PMCID: PMC2795432
- DOI: 10.1038/sj.bjc.6605416
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
Abstract
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers.
Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach.
Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P = 0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P = 0.5) mutation carriers.
Conclusion: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
References
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130 - PMC - PubMed
-
- Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29: 1–11 - PubMed
-
- Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benitez J, Hamann U, Hogervorst FB, Manders P, Ligtenberg MJ, van den Ouweland AM, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82: 937–948 - PMC - PubMed
-
- Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24: 863–871 - PMC - PubMed
-
- Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 9: 104. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 CA069417/CA/NCI NIH HHS/United States
- U01 CA069638/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- NIH0014262027/ImNIH/Intramural NIH HHS/United States
- CA74415/CA/NCI NIH HHS/United States
- U01 CA116167/CA/NCI NIH HHS/United States
- R01 CA116167/CA/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- U01 CA69638/CA/NCI NIH HHS/United States
- R01 CA122340/CA/NCI NIH HHS/United States
- U01 CA069446/CA/NCI NIH HHS/United States
- P50CA116201/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069467/CA/NCI NIH HHS/United States
- RFA-CA-06-503/CA/NCI NIH HHS/United States
- 11022/CRUK_/Cancer Research UK/United Kingdom
- N02-CP-11019-50/CP/NCI NIH HHS/United States
- CAPMC/ CIHR/Canada
- CA122340/CA/NCI NIH HHS/United States
- CA 27469/CA/NCI NIH HHS/United States
- U01 CA069398/CA/NCI NIH HHS/United States
- U10 CA027469/CA/NCI NIH HHS/United States
- C8197/A10123/CRUK_/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- C1287/A8874/CRUK_/Cancer Research UK/United Kingdom
- CA116167/CA/NCI NIH HHS/United States
- U01 CA069631/CA/NCI NIH HHS/United States
- U10 CA037517/CA/NCI NIH HHS/United States
- U01 CA69398/CA/NCI NIH HHS/United States
- U01 CA69446/CA/NCI NIH HHS/United States
- CA 37517/CA/NCI NIH HHS/United States
- U01 CA69631/CA/NCI NIH HHS/United States
- R01 CA074415/CA/NCI NIH HHS/United States
- 10118/CRUK_/Cancer Research UK/United Kingdom
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- U01 CA69467/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous